# TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

> **NCT00741169** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis C
- HCV
- Tuberculosis
- Rifampin
- Pharmacokinetics

## Interventions

- **DRUG:** TMC435350
- **DRUG:** Rifampin
- **DRUG:** TMC435350+rifampin

## Key facts

- **NCT ID:** NCT00741169
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741169, "TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00741169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*